KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug ...

US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. ImmunityBio Inc. (NASDAQ:IBRX) was one ...